CXCR4 and lymphoma: The data on BM samples with or without involvement of DLBCL of our cohort showed a downregulation of CXCR4 in the BM of patients under remission after therapy as well as the correlation of the CXCL12 expression with lymphoma cell infiltration underpins this assumption.